

1655



PTO/SB/92 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED

SEP 25 2002

TECH CENTER 1600/2900

Certificate of Mailing under 37 CFR 1.8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
Robert A. Copeland et al

CASE NO.: PH-7134

APPLICATION NO.: 09/808,832

GROUP ART UNIT: 1653

FILED: MARCH 15, 2001


EXAMINER: J. RUSSEL

FOR: PEPTIDE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR
THERAPEUTIC USE

I hereby certify that this correspondence, a **Response to Restriction Requirement and Postcard** are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231


9-16-2002
Date


Signature

Diane C. Pickering/Depositor
Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

#8 Election
10/10/02
RECEIVED

IN THE APPLICATION OF:

SERIAL NO.:

FILED:

CASE NO.:

GROUP ART UNIT:

EXAMINER:

Copeland et al.

09/808,832

MARCH 15, 2001

PH-7134

1653

J. RUSSEL

SEP 25 2002

TECH CENTER 1600/2900

FOR: PEPTIDE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS
AND THEIR THERAPEUTIC USE

Asst. Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This response is submitted pursuant to the Office Action dated August 16, 2002 to which a response is due on or before September 16, 2002. Claims 1-39 are under consideration.

Responsive to the Official Action dated August 16, 2002, Applicants elect with traverse, the E^{CP} group:

Cap- Paa - Xa2 - Gly - Xp1 - Xp2 - Laa -;

characterized in the restriction requirement for examination purposes only.

Claims 1-14, 15-19, 20-24, 30-32, 33-34 and 35-39 read thereon.

In response to the requirement to elect a single disclosed species, Applicants elect, for initial examination purposes only, SEQ. ID. NO. 186, found on pages 24 and 96. SEQ. ID. NO. 186 is also exemplified by Example 176, a compound of Formula:

acetyl- γ -Glu - Pro - Leu - Gly - Ser(O-benzyl) - Tyr - Leu - Doxorubicin;

found on page 76 in Table 6f. However, Applicants understand this requirement for election of species to be for initial examination purposes only, in accordance with MPEP §803.02, and this should not be a requirement to restrict the scope of the generic and subgeneric claims of this application to such species. If the Office Action is a requirement to restrict the scope of the generic and subgeneric